Your AI-Trained Oncology Knowledge Connection!
Mohammad Jahanzeb, MD, discusses the SystHERs trial, which was designed to provide real-world insight into current treatment patterns, long-term survival, and patient experience with multiple different treatments for HER2-positive metastatic breast cancer.
Andre Goy, MD, highlights what researchers can expect next in the field of mantle cell lymphoma, given recent pivotal data from clinical trials.
Leslie Schover, PhD, discusses strategies to help patients with breast cancer who have sexuality and fertility issues.
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.
Tanguy Seiwert, MD, discussed advances and next steps with immunotherapy, as well as the overall challenges and goals for treating patients with head and neck cancer.
Male breast cancer is a rare and poorly understood disease, but recent molecular studies have revealed fundamental differences from female breast cancer that could help guide treatment strategies toward a more tailored approach.
City of Hope physician Arti Hurria knows what it is like to be a young faculty member balancing life as a doctor, researcher and parent.
Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.
Practice with largest infusion treatment center in Delaware gains access to world-class treatments and enhances its cutting-edge research program.
E. David Crawford, MD, shares insight on incorporating ADT, specifically degarelix, into the prostate cancer landscape and why it remains to be a standard go-to approach for patients.
Michel Sadelain, MD, PhD, discusses CRISPR and its effect on CAR T cells.
The FDA has granted an accelerated approval to the PD-L1 inhibitor avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy.
Susan F. Slovin, MD, PhD, discusses the current state of immunotherapy in prostate cancer.
Robin Zon, MD, responds to questions regarding the fourth annual State of Cancer Care in America report from the American Society of Clinical Oncology.
Scott Tagawa, MD, discusses the latest findings with sacituzumab govitecan in patients with metastatic urothelial cancer.
Sara Hurvitz, MD, discusses the amazing evolution in the available treatment options for patients with HER2-positive breast cancer.
Thomas F. Gajewski, MD, PhD, discusses how the combination of PD-1 and IDO inhibitors could change the standard of care for patients with melanoma, and highlights other emerging targets on the horizon.
Stephan Grupp, MD, PhD, discusses the phase II ELIANA study results and the next steps with chimeric antigen receptor T-cell therapy in acute lymphoblastic leukemia.
Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.
The Affordable Care Act has improved access to cancer care for millions of Americans, and many new drugs and new indications for existing cancer drugs were approved in 2016, but there are frontiers in improving cancer care that include information barriers, disparities in the availability of rural care, and stressors on physicians and oncology practices, ASCO said in its annual report State of Cancer Care in America: 2017.
John E. Mullinax, MD, discusses isolated limb infusion as a limb salvage strategy for locally advanced extremity sarcoma.
Kiran K. Turaga, MD, discusses advances in surgical approaches for the treatment of patients with melanoma.
Ann Marie Beddoe, MD, discusses a study implementing cervical cancer screening and highlights HPV predictors in developing countries.
Hagop Kantarjian, MD, discusses the success of blinatumomab and next steps with the anti-CD19 agent.
Jason J. Luke, MD, discusses adjuvant therapy for patients with melanoma, as well as the future of targeted agents and immunotherapy.
Christopher R. Shea, MD, expresses the importance of expanding melanoma knowledge to more specialists as well as the advancements in pathology over the last several years.
The combination of rituximab, bendamustine, and low-dose cytarabine is an effective induction regimen for elderly patients with mantle cell lymphoma.
In the phase III MONARCH 2 study, adding abemaciclib to fulvestrant improved progression-free survival compared with fulvestrant alone in women with hormone receptor-positive/HER2-negative breast cancer.
Array BioPharma has withdrawn its new drug application for binimetinib as a treatment for patients with NRAS-mutant advanced melanoma, based on feedback from the FDA during a preplanned review meeting.